CompletedPhase 3NCT02027701
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Prof. Dr. Ivo N. van SchaikAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Intervention
- IgPro20(biological)
- Enrollment
- 82 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2017
Study locations (30)
- Site Reference 8400181, Birmingham, Alabama, United States
- Site Reference 8400167, Los Angeles, California, United States
- Site Reference 8400166, Kansas City, Kansas, United States
- Site Reference 8400169, New York, New York, United States
- Site Reference 8400182, Charlotte, North Carolina, United States
- Site Reference 0360017, Woolloongabba, Queensland, Australia
- Site Reference 0360011, Fitzroy, Victoria, Australia
- Site Reference 1240009, Toronto, Ontario, Canada
- Site Reference 1240007, Greenfield Park, Quebec, Canada
- Site Reference 2030009, Hradec Králové, Czechia
- Site Reference 2030002, Hradec Králové, Czechia
- Site Reference 2500022, Nice, France
- Site Reference 2760052, Essen, North Rhine-Westphalia, Germany
- Site Reference 2760069, Berlin, Germany
- Site Reference 2760072, Berlin, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02027701 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →